Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml

We measured serum levels of human glandular kallikrein 2 (hK2) in patients treated with radical retropubic prostatectomy (rrP) for clinically localized prostate cancer (PCa) with a total PSA (tPSA)‐level below 10 ng/ml to investigate whether hK2 can be applied to preoperatively distinguish organ‐confined (pT2a/b) from nonorgan‐confined (≥ pT3a)‐PCa more accurately than total PSA. Further, we evaluated hK2, free‐ and tPSA‐concentrations in all pathologic stages of PCa.

[1]  H. Lilja,et al.  Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. , 1999, Journal of andrology.

[2]  A. Haese*,et al.  Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. , 2000, The Journal of urology.

[3]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[4]  U Pichlmeier,et al.  A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. , 2001, The Journal of urology.

[5]  T. Piironen,et al.  Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. , 2000, Urology.

[6]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[7]  R. Wolfert,et al.  The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. , 1998, Clinical chemistry.

[8]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[9]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[10]  P. Riegman,et al.  Characterization of the human kallikrein locus. , 1992, Genomics.

[11]  T. Piironen,et al.  In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.

[12]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[13]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[14]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[15]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[16]  P. Walsh.  Radical prostatectomy, preservation of sexual function, cancer control. The controversy. , 1987, The Urologic clinics of North America.

[17]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[18]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[19]  R. Wolfert,et al.  Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. , 1998, Urology.

[20]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[21]  D. Tindall,et al.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.

[22]  D. Tindall,et al.  Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. , 1997, Urology.

[23]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[24]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[25]  S. Katusic,et al.  Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. , 1999, The Journal of urology.

[26]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[27]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.